Business Context and Reporting Period
Company: Edgewell Personal Care Company (EPC)
Filing Type: Form 8-K (Current Report)
Date of Report: November 12, 2025
Event: Entry into a Material Definitive Agreement to sell the Feminine Care segment.
Key Financial Metrics and Transaction Terms
- Transaction Consideration: $340 million in cash, subject to customary adjustments for inventory, indebtedness, and other items.
- Assets Involved: Certain assets and assumed liabilities comprising the Company's Feminine Care segment.
- Buyer: Essity Aktiebolag (publ), a Swedish public limited company.
- Termination Fee: $15 million payable by the Buyer to the Company under specific termination circumstances (e.g., breach of regulatory efforts covenants).
- Financial Statements: This filing does not provide current revenue, profit, cash flow, margin, debt, or liquidity metrics for the Company.
Material Changes and Transaction Conditions
The Company has agreed to divest its Feminine Care segment. The transaction is subject to the following material conditions:
- Receipt of required regulatory approvals (including under the Hart-Scott-Rodino Antitrust Improvements Act) or expiration of waiting periods.
- Absence of laws or orders restraining the transaction.
- Accuracy of representations and warranties.
- No material adverse effect on the Business.
- No substantial destruction of manufacturing facilities.
- Receipt of required third-party consents.
Guidance, Outlook, and Risks
Timeline: The transaction must be completed by May 12, 2026. This date may be automatically extended to August 12, 2026, and subsequently to November 12, 2026, if regulatory approvals remain outstanding.
Management Commentary: The Company intends to use reasonable best efforts to consummate the transaction. A transition services agreement will be entered into to support the business post-closing.
Risks and Contingencies:
- Failure to obtain regulatory approvals or satisfy closing conditions.
- Disruptions to business plans and operations during the transition.
- Transaction costs and potential deviation from anticipated impacts.
- General competitive risks, raw material cost fluctuations, and supply chain issues.
Investor Verification Checklist
- Verify the status of regulatory approvals under the HSR Act and other jurisdictions.
- Confirm the final purchase price after customary adjustments for inventory and indebtedness.
- Review the full text of the Asset Purchase Agreement (Exhibit 2.1) for specific representations and warranties.
- Monitor for any material adverse effects on the Feminine Care segment prior to closing.
- Assess the impact of the divestiture on the Company's remaining portfolio and future cash flow.